Summary: “I started this work when I was 18,” reflects MAPS Founder and Executive Director Rick Doblin, Ph.D. “I’m now 67, and we’re still not there. ‘There’ meaning FDA approval, where these drugs are available by prescription.”
Doblin and Ismail L. Ali, J.D., Acting Director of Policy and Advocacy at MAPS, join the California Sun podcast to explain how decades of psychedelic prohibition have severely restricted access to psychedelic-assisted therapies for mental health treatment, and how MAPS continues to work towards the legalization of psychedelic medicine.
Originally appearing here.
